Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jul 16, 2024

Later deadlines: Oct 16, 2024, Nov 16, 2024, Feb 16, 2025, Mar 16, 2025, Jun 16, 2025, Jul 16, 2025, Oct 16, 2025, Nov 16, 2025, Feb 16, 2026, Mar 16, 2026, Jun 16, 2026, Jul 16, 2026, Oct 16, 2026, Nov 16, 2026

Grant amount: Up to US $275,000

Fields of work: Cancer/Oncology

Applicant type: Nonprofit, Government Entity, Indigenous Group, For-Profit Business

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world


NOTE: Optional but encouraged Letters of Intent are due thirty days prior to application due date. All applications for Letters of Intent and Full Proposals are due by 5:00 PM local time of applicant organization. 

The following deadlines apply to standard grant applications:

  • February 16, 2024
  • June 16, 2024
  • October 16, 2024
  • February 16, 2025
  • June 16 , 2025
  • October 16, 2025
  • February 16, 2026
  • June 16, 2026
  • October 16, 2026

The following deadlines apply to Renewal/Resubmission/Revision grant applications:

  • March 16, 2024
  • July 16, 2024
  • November 16, 2024
  • March 16, 2025
  • July 16 , 2025
  • November 16, 2025
  • March 16, 2026
  • July 16, 2026
  • November 16, 2026

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Your history with this funder
No saved opportunities from this funder yet
Save this opportunity to add notes...
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Don't miss out on other good fit funders!

Get personalized grant recommendations, tracking and more by creating a free 14-day account.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed August 26, 2023 and last updated August 26, 2023